Skip to content
Bull Bear Daily

Bull Bear Daily

Primary Menu
  • Home
  • Business
  • Domestic
  • Economy
  • Money
  • Politics
  • Top News
  • Newsletters
  • Home
  • 2026
  • September
  • 28
  • Lilly’s Next Obesity Drug Could Outperform Everything It Sells
  • Economy

Lilly’s Next Obesity Drug Could Outperform Everything It Sells

EASD 2026 opens in Milan today with retatrutide’s 20.8% data, eloraTZP’s Phase 2 debut, and Novo pushing back on two fronts.
Bull Bear Daily September 28, 2026 4 minutes read
934e42dc-9d53-40ac-82d3-866d202b2fc1

Milan’s Allianz MiCo conference center is hosting the 62nd annual meeting of the European Association for the Study of Diabetes this week, and the presentations landing between today and October 2 carry real strategic weight. This is not a routine data dump. For Eli Lilly and Novo Nordisk, the next several days decide whether the pipeline advantage that Lilly has built since Zepbound’s November 2023 FDA approval is durable across a decade, or whether Novo can close the gap before the market scales to the $100 billion level many analysts expect by the 2030s.

Lilly’s centerpiece is retatrutide, an investigational once-weekly triple receptor agonist that hits GIP, GLP-1, and glucagon simultaneously. Phase 3 TRIUMPH-2 results show adults with obesity or overweight and type 2 diabetes lost an average of up to 49.6 lbs (20.8%) and reduced A1C by up to 1.6% at 80 weeks. That number matters for a specific reason: semaglutide targets one receptor and tirzepatide targets two, and early retatrutide readouts have been among the largest weight-loss effects reported in obesity drug trials to date. Lilly is not incrementally improving on Zepbound. It is trying to build a higher-efficacy tier above it.

Lilly says it now has five positive Phase 3 studies supporting retatrutide, and has set a concrete timeline, targeting a Biologics License Application to the FDA in the first quarter of 2027. The full TRIUMPH-2 dataset gets its EASD stage time on Wednesday, September 30.

Alongside retatrutide, Lilly is putting two other molecules in front of the scientific community this week. Phase 3 ACHIEVE-4 data for Foundayo (orforglipron) will also be presented, with hazard ratios of 0.84 for MACE-4 and 0.77 for MACE-3 versus insulin glargine. Foundayo is Lilly’s oral GLP-1, and cardiovascular evidence in type 2 diabetes is exactly the kind of durable moat that keeps patients on a drug for years. Then there is eloraTZP, a combination of eloralintide and tirzepatide. Earlier Phase 1 results showed that eloralintide 3 mg added to tirzepatide 5 mg produced 17% weight loss over 16 weeks, compared with 10% with tirzepatide 5 mg alone. Phase 2 data arrives this week.

Novo’s answer is not nothing. The company says a total of 44 abstracts will be presented, including data across semaglutide, CagriSema, and zenagamtide. Real-world evidence from the OCTANE study will provide insights into Wegovy pill use in adults with overweight or obesity, including weight outcomes, treatment switching and patient-reported outcomes, while CagriSema and amylin-based pipeline data will provide new insights into appetite regulation, eating behaviour, food noise, body composition and bone health. The fMRI work exploring how CagriSema changes brain responses to food cues is genuinely novel science, addressing a patient complaint that has nagged at GLP-1 therapy since the beginning: the mental experience of hunger, not just its physical consequence.

The competitive reality is that Novo must argue quality of effect while Lilly holds the quantity argument. Saying Zepbound has already overtaken Wegovy to become the biggest-selling obesity treatment in the world depends on which geography and time period you mean, and it is not a clean, universally settled claim. What is clear is that tirzepatide has rapidly become one of the largest global incretin franchises. And while CagriSema’s weight loss and blood-sugar reductions have not been tested head-to-head against Zepbound in obesity, a direct comparison has not been completed yet. CagriSema is Novo’s best near-term answer, but retatrutide has not even launched.

For long-term investors, the question is not who wins this week’s conference. It is whether Lilly’s pipeline depth, spanning an oral pill, a best-in-class injectable, a next-generation triple agonist, and now an amylin-combination, is wide enough to hold pricing power and prescription share as the category matures. Lilly’s cardiometabolic strategy is a two-track bet: defend its existing tirzepatide and orforglipron franchises on convenience and established efficacy, while positioning retatrutide as the higher-efficacy option for patients who need more aggressive intervention against obesity’s most serious downstream complications. That is a coherent compounding strategy. Milan this week is where the evidence either deepens that case or complicates it.

Post navigation

Previous: Can Airlines Pass a $195 Barrel of Jet Fuel to Passengers Forever?
Next: Bills going up is good news?

Related Stories

9057dee4-4897-4013-b70c-40646dc33e81
  • Economy

AI Stocks Are Down 74%. Their Bonds Flash the Same Warning.

Bull Bear Daily November 21, 2026
f50c7cf9-872f-4490-b046-7e8763550f40
  • Economy

Brent Fell After Iran Hit Bahrain. That Tells You Everything.

Bull Bear Daily November 16, 2026
59aafdb2-9393-4774-ac7b-df0a4ac0bcdf
  • Economy

Bitcoin Below $70,000 Confirms Crypto Is Now a Rates Trade

Bull Bear Daily November 13, 2026

Live Market Pulse

The charting technology is provided by TradingView. Learn how to use theTradingView Stock Screener.

Sign up for our free Bull Bear Daily Newsletter!

Discover new market trends and ideas directly to your inbox.

By providing your email, you agreed to receive informational and promotional messages from us. You may opt out at any time by clicking the unsubscribe at the bottom of each email. See our Privacy Policy for more information.

Recent Posts

  • Boeing Won’t Say Whether More Engineer Layoffs Are Coming. That’s the Real Production Update.
  • AI Stocks Are Down 74%. Their Bonds Flash the Same Warning.
  • Seven Down Days, One Key Number: Is the S&P 500 Correction All About Nvidia?
  • Accor’s €1.6bn Ennismore Bet Triggers a Fight for Its Future
  • Gap Earned 30% More on Flat Sales. Ross Grew Everything and Still Got Punished.
  • Intel Just Got Its First Real Foundry Customer
  • Nvidia’s China Wildcard: Can Trump’s Promise Beat Congress?

You may have missed

24a70d4d-94d3-4b9d-a493-6a06a0dc6407
  • Top News

Boeing Won’t Say Whether More Engineer Layoffs Are Coming. That’s the Real Production Update.

Bull Bear Daily November 22, 2026
9057dee4-4897-4013-b70c-40646dc33e81
  • Economy

AI Stocks Are Down 74%. Their Bonds Flash the Same Warning.

Bull Bear Daily November 21, 2026
21dafaee-9045-41a1-8e6c-0c23b4880888
  • Top News

Seven Down Days, One Key Number: Is the S&P 500 Correction All About Nvidia?

Bull Bear Daily November 21, 2026
b68d5628-4ac3-4848-97c5-a616be9e2ca9
  • Business

Accor’s €1.6bn Ennismore Bet Triggers a Fight for Its Future

Bull Bear Daily November 20, 2026
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms of Service/Use Agreement
  • Contact Us
Copyright 2026 © All rights reserved | Bull Bear Daily | bullbeardaily.com
SITE_OK
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}